The prescription drug cost effectiveness analyses conducted by the independent Institute for Clinical and Economic Review could serve as the basis for value-based contracting in government-sponsored insurance, organizations representing payers and health care providers suggest in recent comments to HHS.
ICER Value Assessments Could Provide US Standard, Payers, Providers Tell HHS
Comments to HHS on the Trump Administration’s US drug pricing blueprint recommend that cost effectiveness analyses by the Institute for Clinical and Economic Review could help promote value-based pricing.